Breaking News

Hope Bio Gets FDA Nod to Start First Stem Cell COVID-19 Clinical Trial

Autologous mesenchymal stem cells to provide immune support against COVID-19

By: Contract Pharma

Contract Pharma Staff

Hope Biosciences, a clinical stage biotech focused on developing cell-based therapeutics for acute and chronic disease, said FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase I/II clinical trial for rheumatoid arthritis, results appeared to show that HB-a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters